Compare Bristol-Myers Squibb Co (BMY) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Strategy Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Strategy Inc. trades at $97.4 (market cap $37.84B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.4× Strategy Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| BMY | MSTR | |
|---|---|---|
Market Cap | $129.94B | $37.84B |
Sector | Health | Technology |
52-Week High | $65.89 | $394.39 |
52-Week Low | $42.60 | $82.31 |
Enterprise Value | $163.92B | $56.61B |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
